Tags

Type your tag names separated by a space and hit enter

Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.
MMWR Morb Mortal Wkly Rep. 2021 Dec 10; 70(49):1700-1705.MM

Abstract

The mRNA COVID-19 vaccines (Moderna and Pfizer-BioNTech) provide strong protection against severe COVID-19, including hospitalization, for at least several months after receipt of the second dose (1,2). However, studies examining immune responses and differences in protection against COVID-19-associated hospitalization in real-world settings, including by vaccine product, are limited. To understand how vaccine effectiveness (VE) might change with time, CDC and collaborators assessed the comparative effectiveness of Moderna and Pfizer-BioNTech vaccines in preventing COVID-19-associated hospitalization at two periods (14-119 days and ≥120 days) after receipt of the second vaccine dose among 1,896 U.S. veterans at five Veterans Affairs medical centers (VAMCs) during February 1-September 30, 2021. Among 234 U.S. veterans fully vaccinated with an mRNA COVID-19 vaccine and without evidence of current or prior SARS-CoV-2 infection, serum antibody levels (anti-spike immunoglobulin G [IgG] and anti-receptor binding domain [RBD] IgG) to SARS-CoV-2 were also compared. Adjusted VE 14-119 days following second Moderna vaccine dose was 89.6% (95% CI = 80.1%-94.5%) and after the second Pfizer-BioNTech dose was 86.0% (95% CI = 77.6%-91.3%); at ≥120 days VE was 86.1% (95% CI = 77.7%-91.3%) for Moderna and 75.1% (95% CI = 64.6%-82.4%) for Pfizer-BioNTech. Antibody levels were significantly higher among Moderna recipients than Pfizer-BioNTech recipients across all age groups and periods since vaccination; however, antibody levels among recipients of both products declined between 14-119 days and ≥120 days. These findings from a cohort of older, hospitalized veterans with high prevalences of underlying conditions suggest the importance of booster doses to help maintain long-term protection against severe COVID-19.†.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

34882654

Citation

Bajema, Kristina L., et al. "Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines Among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021." MMWR. Morbidity and Mortality Weekly Report, vol. 70, no. 49, 2021, pp. 1700-1705.
Bajema KL, Dahl RM, Evener SL, et al. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(49):1700-1705.
Bajema, K. L., Dahl, R. M., Evener, S. L., Prill, M. M., Rodriguez-Barradas, M. C., Marconi, V. C., Beenhouwer, D. O., Holodniy, M., Lucero-Obusan, C., Brown, S. T., Tremarelli, M., Epperson, M., Mills, L., Park, S. H., Rivera-Dominguez, G., Morones, R. G., Ahmadi-Izadi, G., Deovic, R., Mendoza, C., ... Surie, D. (2021). Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021. MMWR. Morbidity and Mortality Weekly Report, 70(49), 1700-1705. https://doi.org/10.15585/mmwr.mm7049a2
Bajema KL, et al. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines Among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021. MMWR Morb Mortal Wkly Rep. 2021 Dec 10;70(49):1700-1705. PubMed PMID: 34882654.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021. AU - Bajema,Kristina L, AU - Dahl,Rebecca M, AU - Evener,Steve L, AU - Prill,Mila M, AU - Rodriguez-Barradas,Maria C, AU - Marconi,Vincent C, AU - Beenhouwer,David O, AU - Holodniy,Mark, AU - Lucero-Obusan,Cynthia, AU - Brown,Sheldon T, AU - Tremarelli,Maraia, AU - Epperson,Monica, AU - Mills,Lisa, AU - Park,So Hee, AU - Rivera-Dominguez,Gilberto, AU - Morones,Rosalba Gomez, AU - Ahmadi-Izadi,Ghazal, AU - Deovic,Rijalda, AU - Mendoza,Chad, AU - Jeong,Chan, AU - Schrag,Stephanie J, AU - Meites,Elissa, AU - Hall,Aron J, AU - Kobayashi,Miwako, AU - McMorrow,Meredith, AU - Verani,Jennifer R, AU - Thornburg,Natalie J, AU - Surie,Diya, AU - ,, AU - ,, AU - ,, Y1 - 2021/12/10/ PY - 2021/12/9/entrez PY - 2021/12/10/pubmed PY - 2021/12/15/medline SP - 1700 EP - 1705 JF - MMWR. Morbidity and mortality weekly report JO - MMWR Morb Mortal Wkly Rep VL - 70 IS - 49 N2 - The mRNA COVID-19 vaccines (Moderna and Pfizer-BioNTech) provide strong protection against severe COVID-19, including hospitalization, for at least several months after receipt of the second dose (1,2). However, studies examining immune responses and differences in protection against COVID-19-associated hospitalization in real-world settings, including by vaccine product, are limited. To understand how vaccine effectiveness (VE) might change with time, CDC and collaborators assessed the comparative effectiveness of Moderna and Pfizer-BioNTech vaccines in preventing COVID-19-associated hospitalization at two periods (14-119 days and ≥120 days) after receipt of the second vaccine dose among 1,896 U.S. veterans at five Veterans Affairs medical centers (VAMCs) during February 1-September 30, 2021. Among 234 U.S. veterans fully vaccinated with an mRNA COVID-19 vaccine and without evidence of current or prior SARS-CoV-2 infection, serum antibody levels (anti-spike immunoglobulin G [IgG] and anti-receptor binding domain [RBD] IgG) to SARS-CoV-2 were also compared. Adjusted VE 14-119 days following second Moderna vaccine dose was 89.6% (95% CI = 80.1%-94.5%) and after the second Pfizer-BioNTech dose was 86.0% (95% CI = 77.6%-91.3%); at ≥120 days VE was 86.1% (95% CI = 77.7%-91.3%) for Moderna and 75.1% (95% CI = 64.6%-82.4%) for Pfizer-BioNTech. Antibody levels were significantly higher among Moderna recipients than Pfizer-BioNTech recipients across all age groups and periods since vaccination; however, antibody levels among recipients of both products declined between 14-119 days and ≥120 days. These findings from a cohort of older, hospitalized veterans with high prevalences of underlying conditions suggest the importance of booster doses to help maintain long-term protection against severe COVID-19.†. SN - 1545-861X UR - https://www.unboundmedicine.com/medline/citation/34882654/Comparative_Effectiveness_and_Antibody_Responses_to_Moderna_and_Pfizer_BioNTech_COVID_19_Vaccines_among_Hospitalized_Veterans___Five_Veterans_Affairs_Medical_Centers_United_States_February_1_September_30_2021_ DB - PRIME DP - Unbound Medicine ER -